News 
Market Data 
Discover
Replies to post #92337 on NanoViricides Inc. (NNVC)
06/20/14 12:21 PM
Nanotechnology is the study and manipulation of matter at the molecular, or nanometer, scale.4 A nanoviricide, unlike current vaccines, is a manmade molecule engineered to replace the antibody in the immune system. The nanoviricide works similarly to the antibody, for both selectively tag the virus when it first presents itself; however, the nanoviricide attaches to the virus particle at several sites, using a sort of cluster mechanism, giving it the ability to grasp the virus while encapsulating it and destroying it. This is possible based on the two-part design of the nanoviricide.4 The first is the nanomicelle, or the casing of the nanoviricide. This casing opens up and encapsulates the virus, and by physical and chemical forces, breaks down the virus into harmless pieces. The second feature is the receptor molecule, which is ligand mimicking, meaning that it presents the same chemical features as a normal cell, and creates several binding sites for the virus. Hence we call the nanoviricide a “multisite target,” whereas the antibody attaches at one. The nanoviricide particle recognizes multiple sites and binds to them (currently binding to as many as three different sites) for a highly effective attack. How does the virus allow the binding if it is so specific? Like the surface of a cell, the nanoviricide does not change form, tricking the virus into assuming it has attached to a vulnerable cell. The nanoviricide, disguised as an injured cell, then coats the virus particle with degenerating chemicals, which ultimately renders the virus ineffective, prompting it to disintegrate.4 The nanoviricide dismantles the virus without any immune system assistance, avoiding many of aforementioned issues with current vaccine production mechanisms.
There will always be a need and demand for vaccines, but many people won’t use them. We know this from experience. However, the existence of a nanoviricide treatment for a virus-borne illness means that treatment can begin after symptoms for influenza or some other virus-borne disease appear.
Based on animal studies, we believe that virus populations will be so reduced that symptoms would disappear in only a few hours. Immunity, however, would develop in the normal 21-day period so that the patient could not get the same infection again.
Some viruses—notably hepatitis, HIV, and herpes—might not be cleared entirely from the system because they hide inside various tissues. I believe, however, that symptoms will disappear, and the patient would not be contagious. When the virus emerges, however, it will encounter nanoviricides if they are in the patient’s system. Over time, there is a strong possibility that each reemergence will be smaller than the last, until the disease is gone. ~Mauldin Economics - Build Transformational Wealth from Three Tiny Companies
The Company has previously reported unprecedented anti-HIV efficacy from our previous anti-HIV drug candidate, matching or exceeding the effectiveness level of a three drug HAART cocktail in the standard humanized mouse model studies. In this mouse model, the mouse immune system is wiped out and replaced by human immune system, thereby allowing drug effects against HIV-1 infection of human T cells to be observed. In August 2011, the Company reported that it had identified an anti-HIV ligand that was superior to the ones employed by us previously. This new ligand was identified as superior by employing a less effective backbone polymer to make the nanoviricides for the 2011 study. In this study, the clinical benefit of HIVCide was found to be sustained for at least four weeks after the last drug dose. Treatment with the lead anti-HIV nanoviricide both (1) reduced the HIV viral load and (2) also protected the human T cells (CD4+,CD8+), equally well as compared to treatment with the three-drug HAART cocktail, at 24-days as well as at 48-days, even though the HIVCide treatment was stopped at 20 days. In addition, the lead HIVCide drug candidate provided these clinical benefits at a much lower drug load than that of the HAART therapy.
With further optimization, the Company believes that it has now achieved extremely high efficacy levels for its lead and backup HIVCide candidates. Further optimization of the nanomicelle portion of the anti-HIV drug candidates is now in progress.
